Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug;9(15):1264. doi: 10.21037/atm-21-525

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2021 Annals of Translational Medicine. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

Variant allele frequency dynamics over time in cell-free DNA and white blood cells with corresponding PET-CT images. Images from left to right: baseline PET-CT image showing FDG-avid esophageal tumor; CRE-II (t=3) PET-CT image showing radiologically complete response to nCRT; PET-CT image at 21 months after baseline (t=5) showing FDG-avid lesion suspect for metastasis within the semimembranosus muscle; PET-CT image 26 months after baseline (t=7) of semimembranosus lesion showing decreased intensity after induction chemotherapy; PET-CT image 30 months after baseline (t=9) showing FDG-avid lesions suspect for metastasis within the adductor muscles of the right lower extremity, bilaterally in the pelvic acetabulum and in the transverse process of a thoracic vertebra. VAF, variant allele frequency; cfDNA, cell-free deoxyribonucleic acid; WBCs, white blood cells; PET-CT, positron emission tomography-computed tomography; nCRT, neoadjuvant chemoradiotherapy; FDG, 18-fluoride-fluorodeoxyglucose; CRE-II clinical response evaluation-II.